Abstract
Antiphospholipid antibody (APLA) syndrome (APS) is a heterogeneous disorder defined by the finding of persistent APLA in patients with arterial or venous thrombosis or pregnancy morbidity. APS manifestations range from deep vein thrombosis to stroke and even rapid multiorgan failure (the rare “catastrophic APS”). APS may be primary or secondary; in both cases, however, the clinical consequences appear to be the same. Although crucial to thrombotic risk assessment and clinical management, current laboratory testing for APLA lacks standardization and data from randomized trials. Consequently, correlating laboratory findings with clinical features is still a challenge for clinicians facing APS. This chapter presents the current definition of APS and discusses its etiopathogenesis and diagnosis and approaches for its treatment.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Wassermann A, Neisser A, Bruck C (1906) Eine serodiagnostische reaction bei Syphilis. Dtsch Med Wochenschr 32:745–746
Matsuura E, Igasrashi Y, Fujimoto M et al (1992) Heterogeneity of anticardiolipin antobodies defined by anticardiolipin cofactor. J Immunol 144:3885–3891
Forestiero RR, Martinuzzo ME, Kordich LC, Carreras LO (1996) Reactivity to β2-glycoprotein I clearly differentiates anticardiolipin antibodies from anti-phospholipid syndrome and syphilis. Thromb Haemost 75:717–720
Triplett DA (2002) Antiphospholipid antibodies. Arch Pathol Lab Med 126:1424–1429
Brandt JT, Triplett DA, Alving B, Scharrer I (1995) Criteria for the diagnosis of lupus anticoagulants: an update. Thromb Haemost 74:1185–1190
Tripodi A, Chantarangkul V, Clerici M et al (2002) Laboratory diagnosis of lupus anticoagulant treatment. Performance of dilute Russell viper venom test and silica clotting time in comparison with Staclot LA. Thromb Haemost 88:583–586
Harris EN, Pierangeli SS (2002) Revisiting the anticardiolipin test and its standardization. Lupus 11:269–275
Harris EN (1990) Special report: the second international anti-cardiolipin standardization workshop/the Kingston Anti-Phospholipid Antibody Study (KAPS) group. Am J Clin Pathol 94:476–484
Long AA, Ginsberg JS, Brill-Edwards P et al (1991) The relationship of antiphospholipid antibodies to thromboembolic disease in systemic lupus erythematosus: a cross-sectional study. Thromb Haemost 66:520–524
Galli M, Luciani D, Bertolini G, Barbui T (2003) Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood 102:2717–2723
de Groot PG, Horbach DA, Simmelink MJ et al (1998) Anti-prothrombin antibodies and their ralation with thrombosis and lupus anticoagulant. Lupus 7(Suppl 2):S32–S36
Satoh A, Suzuki K, Takayama E et al (1999) Detection of anti-annexin IV and V antibodies in patients with antiphospholipid syndrome and systemic lupus erythematosus. J Rheumatol 26:1715–1720
de Groot PG, Derksen RH (2005) Pathophysiology of the antiphospholipid syndrome. J Thromb Haemost 3:1854–1860
Hemker HC, Dieri RA, De Smedt E, Béguin S (2006) Thrombin generation, a function test of the haemostatic-thrombotic system. Thromb Haemost 96:553–561
Membre A, Wahl D, Latger-Cannard V et al (2008) The effect of platelet activation on the hypercoagulability induced by murine monoclonal antiphospholipid antibodies. Haematologica 93:566–573
Vila P, Hernandez MC, Lopez-Fernandez MF et al (1994) Prevalence, follow-up and clinical significance of the anticardiolipin antibodies in normal subjects. Thromb Haemost 72:209–213
Ginsberg JS, Wells PS, Brill-Edwards P et al (1995) Antiphospholipid antibodies and venous thromboembolism. Blood 86:3685–3691
Mateo J, Oliver A, Borrell M et al (1997) Laboratory evaluation and clinical characteristic of 2,132 consecutive unselected patients with venous thromboembolism: results of the Spanish multicentric study on thrombophilia (EMET-study). Thromb Haemost 77:444–451
Galli M, Luciani D, Bertolini G et al (2003) Lupus anticoagulants are stronger risk factor for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 101:1827–1832
Wilson WA, Gharavi AE, Koike T et al (1999) International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 42:1309–1311
Miyakis S, Lockshin MD, Atsumi T et al (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4:295–306
Tincani A, Allegri F, Sanmarco M et al (2001) Anticardiolipin antibody assay: a methodological analysis for a better consensus in routine determinations: a cooperative project of the European antiphospholipid forum. Thromb Haemost 86:575–583
Brandt JT, Barna LK, Triplett DA (1995) Laboratory identification of lupus anticoagulants: results of the second international workshop for identification of lupus anticoagulants. Thromb Haemost 74:1597–1603
Asherson RA (1992) The catastrophic antiphospholipid syndrome. J Rheumatol 19:508–512
Bucciarelli S, Espinosa G, Cervera R et al (2006) For the CAPS registry project group (european forum on antiphospholipid antibodies): mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients. Arthritis Rheum 54:2568–2576
Cervera R, Piette JC, Font J et al (2002) Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 46:1019–1027
Asherson RA, Cervera R, Piette JC et al (1998) Catastrophic antiphospholipid syndrome: clinical and laboratory features of 50 patients. Medicine (Baltimore) 77:195–207
Dentali F, Crowther M (2010) Antiphospholipid antibodies in critical illness. Crit Care Med 38(Suppl 2):S51–S56
Kitchens CS (1998) Thrombotic storm: when thrombosis begets thrombosis. Am J Med 104:381–385
Meroni PL (2008) Pathogenesis of the antiphospholipid syndrome: an additional example of the mosaic of the autoimmunity. J Autoimmun 30:99–103
Espinosa G, Cervera R (2009) Morbidity and mortality in the antiphosholipid syndrome. Curr Opin Pulm Med 15:413–417
Hudson M, Herr AL, Rauch J et al (2003) The presence of multiple prothrombotic risk factors is associated with a higher risk of thrombosis in individuals with anticardiolipin antibodies. J Rheumatol 30:2385–2391
Schulman S, Svenungsson E, Granqvist S (1998) Duration of Anticoagulation Study Group: anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Am J Med 104:332–338
Kearon C, Gent M, Hirsh J et al (1999) A comparison of three month of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 340:901–907
Kearon C, Ginsberg JS, Kovacs MJ et al (2003) Comparison of low-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 349:631–639
Rosove MH, Brewer PM (1992) Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med 117:303–308
Khamashta MA, Cuadrato MJ, Mujic F et al (1995) The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 332:993–997
Finazzi G, Brancaccio V, Moia M et al (1996) Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four years prospective study from the Italian Registry. Am J Med 100:530–536
Tsapanos V, Kanellopoulos N, Cardamakis E et al (2000) Anticardiolipin antibodies level in healthy pregnant and non-pregnant women. Arch Gynecol Obstet 263:111–115
Oshiro BT, Silver RM, Scott JR et al (1996) Antiphospholipid antibodies and fetal death. Obstet Gynecol 87:489–493
Rai RS, Clifford K, Cohen H et al (1995) High prospective fetal loss rate in untreated pregnancies of women with recurrent miscarriage and antiphospholipid antibodies. Hum Reprod 10:3301–3304
Branch DW, Silver RM, Blackwell JL, Reading JC, Scott JR (1992) Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of the Utah experience. Obstet Gynecol 80:614–620
Out HJ, Bruinse HW, Christiens GC et al (1992) A prospective, controlled, multicenter study on the obstetric risk in pregnant women with antiphospholipid antibodies. Am J Obstet Gynecol 167:26–32
Buller HR, Agnelli G, Hull RD et al (2004) Antithrombotic therapy for venous thromboembolic disease: the seventh ACCP conference on antithrombotic and thrombolitic therapy. Chest 126:401S–428S
Garcia DA, Khamashta MA, Crowther MA (2007) How we diagnose and treat thrombotic manifestations of the antiphospholipid syndrome: a case-based review. Blood 110:3122–3127
Crowther MA, Ginsberg JS, Julian J et al (2003) A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 349:1133–1138
Finazzi G, Marchioli R, Brancaccio V et al (2005) A randomized clinical trial of high-intensity warfarin vs conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost 3:848–853
Tenedios F, Erkan D, Lockshin MD (2005) Cardiac involvement in the antiphospholipid syndrome. Lupus 14:691–696
The APASS Writing Committee (2004) Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA 2004 291:576–584
Mohr JP, Thompson JL, Lazar RM et al (2001) A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 345:1444–1451
Brey RL, Chapman J, Levin SR et al (2003) Stroke and antiphospholipid syndrome: consensus meeting Taormina 2002. Lupus 12:508–513
Okuma H, Kitagawa Y, Yasuda T et al (2009) Comparison between single antiplatelet therapy and combination of antiplatelet and anticoagulation therapy for secondary prevention in ischemic stroke patients with antiphospholipid syndrome. Int J Med Sci 7:15–18
Alagorn-Segovia D, Boffa MC, Branch W et al (2003) Prophylaxis of the antiphospholipid syndrome: a consensus report. Lupus 12:499–503
Erkan D, Harrison MJ, Levi R et al (2007) Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-bind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum 56:2382–2391
Vivaldi P, Rossetti G, Galli M, Finazzi G (1997) Severe bleeding due to acquired hypoprothrombinemia-lupus anticoagulant syndrome. Case report and review of literature. Haematologica 82:345–347
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer-Verlag Italia
About this chapter
Cite this chapter
Zambon, M., Cappelli, D., Berlot, G. (2012). Antiphospholipid Antibody Syndrome. In: Berlot, G. (eds) Hemocoagulative Problems in the Critically Ill Patient. Springer, Milano. https://doi.org/10.1007/978-88-470-2448-9_13
Download citation
DOI: https://doi.org/10.1007/978-88-470-2448-9_13
Published:
Publisher Name: Springer, Milano
Print ISBN: 978-88-470-2447-2
Online ISBN: 978-88-470-2448-9
eBook Packages: MedicineMedicine (R0)